November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
Nov 19, 2025, 17:02

Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

Eptacog Beta Beyond Labels: Spanish Real-World Evidence

  • 8 patients | 2 Madrid centres | 3 rare bleeding disorders
  • On-Label Treatments (HA + Inhibitors; n=4)
  • 3/4 on concurrent emicizumab (excluded from PERSEPT trials)
  • Dosing: 75 µg/kg
  • Breakthrough control + thrombotic safety
  • Severe iliopsoas haematoma: 70 infusions → complete resolution, zero thrombotic events

Off-Label Treatments (n=4)

  • Factor VII deficiency (n=3): Perioperative surgery with 15–20 µg/kg—excellent haemostasis, zero bleeding complications
  • Steroid-refractory acquired haemophilia (n=1): High-titre inhibitor case reflects poor-prognosis disease biology

No Safety Signal: Zero thrombotic/thromboembolic complications across all patients

As emicizumab, concizumab, marstacimab and fitusiran transform prophylaxis of haemophilia, eptacog beta emerges as a versatile rescue therapy.

This real-world experience expands treatment paradigms beyond current labels—pending validation from further studies.

Congratulations to the authors!”

Read the full article here.

Article: Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience

Authors: Jose Manuel Martin de Bustamante, María Isabel Rivas-Pollmar, Natalia Acedo, Nora Butta, Victor Jimenez-Yuste, Maria Teresa Álvarez-Román

Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain

Stay updated on all scientific advances with Hemostasis Today.